Blog
RSS FeedPosted by Michael Wonder on 16 Mar 2017
The Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils
15 March 2017 - New members bring expertise in broad range of perspectives, including bioethics, patient advocacy, policy, and clinical ...
Posted by Michael Wonder on 11 Mar 2017
Institute for Clinical and Economic Review releases revised report on targeted immune modulators for treatment of rheumatoid arthritis
10 March 2017 - Analyses of evidence on comparative effectiveness raise questions about current step therapy protocols, while net prices for ...
Posted by Michael Wonder on 07 Mar 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for ovarian cancer
6 March 2017 - Document will be open to public comment until 27 March 2017. ...
Posted by Michael Wonder on 06 Mar 2017
ICER's final report on disease-modifying therapies for multiple sclerosis finds most drugs are over-priced in relation to benefits for patients; highlights need for stakeholder collaboration to address system issues
6 March 2017 - Key policy recommendations call on manufacturers to cease price increases and payers to ease coverage restrictions and ...
Posted by Michael Wonder on 03 Mar 2017
Institute for Clinical and Economic Review publishes white paper on assessment and payment methods for gene therapies
3 March 2017 - Paper presents recommendations for improving evidence generation and assessment methods for gene therapies; also analyses the ...
Posted by Michael Wonder on 08 Feb 2017
Institute for Clinical and Economic Review to review treatments for ovarian cancer in upcoming report
8 February 2017 - Preliminary list of drugs to be reviewed includes rucaparib, niraparib and olaparib. ...
Posted by Michael Wonder on 07 Feb 2017
Assessing the value of drugs for rare conditions: Institute for Clinical and Economic Review to host orphan drug assessment and pricing summit
7 February 2017 - Discussion will be anchored by an ICER Briefing Paper evaluating the evidence on the comparative clinical effectiveness ...
Posted by Michael Wonder on 01 Feb 2017
Institute for Clinical and Economic Review posts revised value assessment framework for public comment
1 February 2017 - Dr. Steven Pearson, ICER's President, will present proposed changes during 13 February webinar. ...
Posted by Michael Wonder on 27 Jan 2017
Institute for Clinical and Economic Review releases evidence report on disease-modifying therapies for multiple sclerosis, including daclizumab and ocrelizumab
26 January 2017 - Report finds alemtuzumab represents best long-term cost-effectiveness; prices for most drugs not well-aligned with added value ...
Posted by Michael Wonder on 22 Jan 2017
ICER releases draft evidence report on treatments for rheumatoid arthritis
20 January 2017 - Public comment period now open - comments accepted until 17 February. ...
Posted by Michael Wonder on 06 Dec 2016
ICER posts draft scoping document on treatments for osteoporosis
5 December 2016 - Document will be open to public comment until 23 December 2016. ...
Posted by Michael Wonder on 02 Dec 2016
ICER's final report on targeted immunomodulators for plaque psoriasis offers guidance for policy and practice
2 December 2016 - Independent CEPAC votes on value and subsequent policy roundtable discussion suggest that drug prices after rebates ...
Posted by Michael Wonder on 13 Nov 2016
ICER to review drug treatments for osteoporosis in upcoming report
11 November 2016 - The ICER will develop a report assessing the comparative clinical effectiveness and value of emerging drug ...
Posted by Michael Wonder on 20 Oct 2016
Oncologists knock ICER's lung cancer cost-effectiveness review
20 October 2016 - Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for new medicines ...
Posted by Michael Wonder on 19 Oct 2016
ICER to review treatments for atopic dermatitis in upcoming report
19 October 2016 - The Institute for Clinical and Economic Review will develop a report assessing the comparative clinical effectiveness ...